Shkreli charges prompt Nasdaq to delist KaloBios

Martin Shkreli has already been ousted as CEO of KaloBios ($KBIO). And now, Nasdaq plans to delist the company, citing Shkreli's recent arrest on fraud and looting charges as one reason for the move. More from FierceBiotech

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…